Blood cancers

Blood cancer drugs approved on the basis of flimsy trial data

The quality of clinical trials for new cancer therapies leaves room for improvement, according to an article in the latest BMJ. An analysis of 54 pivotal studies, which led to the European Medicines Agency (EMA) approval of 32 novel targeted therapies and immunotherapy drugs for cancers between 2014 and 2016, found almost half the trials ...

Already a member?

Login to keep reading.

© 2021 the limbic